Lung transplantation - Opportunities for research and clinical advancement

被引:70
作者
Wilkes, DS
Egan, TM
Reynolds, HY
机构
[1] NHLBI, DLD, Bethesda, MD 20892 USA
[2] Univ N Carolina, Chapel Hill, NC 27514 USA
[3] Indiana Univ, Sch Med, Indianapolis, IN USA
关键词
allograft dysfunction; infection; ischemia-reperfusion injury; lung transplantation; obliterative bronchiolitis; rejection;
D O I
10.1164/rccm.200501-098WS
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Lung transplantation is the only definitive therapy for many forms of end-stage lung diseases. However, the success of lung transplantation is limited by many factors: (1) Too few lungs available for transplantation due to limited donors or injury to the donor lung; (2) current methods of preservation of excised lungs do not allow extended periods of time between procurement and implantation; (3) acute graft failure is more common with lungs than other solid organs, thus contributing to poorer short-term survival after lung transplant compared with that for recipients of other organs; (4) lung transplant recipients are particularly vulnerable to pulmonary infections; and (5) chronic allograft dysfunction, manifest by bronchiolitis obliterans syndrome, is frequent and limits long-term survival. Scientific advances may provide significant improvements in the outcome of lung transplantation. The National Heart, Lung, and Blood Institute convened a working group of investigators on June 14-15, 2004, in Bethesda, Maryland, to identify opportunities for scientific advancement in lung transplantation, including basic and clinical research. This workshop provides a framework to identify critical issues related to clinical lung transplantation, and to delineate important areas for productive scientific investigation.
引用
收藏
页码:944 / 955
页数:12
相关论文
共 160 条
[131]  
STRAYER DS, 1993, J BIOL CHEM, V268, P18679
[132]   In vivo adenovirus-mediated endothelial nitric oxide synthase gene transfer ameliorates lung allograft ischemia-reperfusion injury [J].
Suda, T ;
Mora, BN ;
D'Ovidio, F ;
Cooper, JA ;
Hiratsuka, M ;
Zhang, WJ ;
Mohanakumar, T ;
Patterson, GA .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2000, 119 (02) :297-303
[133]   Role of autoimmunity in organ allograft rejection: a focus on immunity to type V collagen in the pathogenesis of lung transplant rejection [J].
Sumpter, TL ;
Wilkes, DS .
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2004, 286 (06) :L1129-L1139
[134]   SUCCESSFUL OUTCOME OF LUNG TRANSPLANTATION IS NOT COMPROMISED BY THE USE OF MARGINAL DONOR LUNGS [J].
SUNDARESAN, S ;
SEMENKOVICH, J ;
OCHOA, L ;
RICHARDSON, G ;
TRULOCK, EP ;
COOPER, JD ;
PATTERSON, GA .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1995, 109 (06) :1075-1080
[135]  
SUNDARESAN S, 1995, J HEART LUNG TRANSPL, V14, P512
[136]   Inhibitory effect of macrolides on interleukin-8 secretion from cultured human nasal epithelial cells [J].
Suzuki, H ;
Shimomura, A ;
Ikeda, K ;
Furukawa, M ;
Oshima, T ;
Takasaka, T .
LARYNGOSCOPE, 1997, 107 (12) :1661-1666
[137]  
TAKASHIMA S, 2003, AM J RESP CRIT CARE, V167, pA363
[138]  
TENNER AJ, 1989, J BIOL CHEM, V264, P13923
[139]   Antisense intercellular adhesion molecule-1 (ICAM-1) oligodeoxyribonucleotide delivered during organ preservation inhibits posttransplant ICAM-1 expression and reduces primary lung isograft failure [J].
Toda, K ;
Kayano, K ;
Karimova, A ;
Naka, Y ;
Fujita, T ;
Minamoto, K ;
Wang, CY ;
Pinsky, DJ .
CIRCULATION RESEARCH, 2000, 86 (02) :166-174
[140]  
*US DEP HHS, 2004, 2003 ANN REP US ORG